Curis Inc CRIS.OQ reported a quarterly adjusted loss of $1.70 per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-2.13. The mean expectation of six analysts for the quarter was for a loss of $1.83 per share. Wall Street expected results to range from $-2.11 to $-1.62 per share.
Revenue rose 3.5% to $2.93 million from a year ago; analysts expected $2.28 million.
Curis Inc's reported EPS for the quarter was a loss of $1.70.
The company reported a quarterly loss of $10.09 million.
Curis Inc shares had fallen by 27.1% this quarter and lost 69.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 3.4% in the last three months.
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Curis Inc is 20.00
This summary was machine generated from LSEG data November 14 at 08:55 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Sep. 30 2024 | -1.83 | -1.70 | Beat |
Jun. 30 2024 | -1.67 | -2.03 | Missed |
Mar. 31 2024 | -2.12 | -2.05 | Beat |
Dec. 31 2023 | -2.11 | -2.03 | Beat |
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.